Alaric has been covering the biopharma industry and health care for more than 14 years. His areas of focus include clinical trials, drug development in hematology-oncology, cell and gene therapy and the industry's growing use of artificial intelligence and machine learning. He holds a bachelor's degree in journalism from Ball State University and previously lived in China for three years.

Latest from Alaric DeArment

BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia

The drugmaker announced topline results from the Phase III INDEPENDENCE trial, which did meet key secondary endpoints.

33 States Agree To Standardized Access Policies In Medicaid Sickle Cell Payment Demo

States also agreed to fund patient travel to specialized treatment centers as part of their participation in the Medicaid demo of CMS-negotiated outcomes-based contracts for Vertex/CRISPR's Casgevy and bluebird bio's Lyfgenia.

BMS/Pfizer To Sell Discounted Eliquis Direct – And Other Drugmakers May Follow Suit

Analysts see the new strategy as a way to address pressure from the Trump administration’s most favored nation drug pricing proposals.

Hopes Rise For Sickle Cell Gene Therapy Access As 33 States Join CMS Program

CMS said that 33 US states plus the District of Columbia and Puerto Rico had joined a program whereby the agency negotiates outcomes-based contracts on their behalf.

Sellas Targets Tambiciclib To Adverse-Risk Frontline AML Patients After Phase II Success

The biotech announced positive Phase II data for the drug combined with AbbVie/Roche’s Venclexta and BMS’s Vidaza in relapsed/refractory acute myeloid leukemia.

Takeda Prepares Ground For Oveporexton In Narcolepsy

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.